Compounds from Anisomeles Heyneana

Abstract

The present invention describes use of compounds of formula 1 or 2 or their compositions for the treatment of leukemia and use of compound of formula 1 or its composition for treatment of infections caused due to M. tuberculosis. The invention further discloses use of compound of formula 3 for the conversion of solar energy into electric current in dye sensitized solar cells. Also, the present invention discloses a process of extraction of compounds of formula 1 or 2 or 3 from the extract of aerial parts of Anisomeles heyneana

1 . A pharmaceutical composition comprising at least one compound selected from formula 1 and formula 2 along with pharmaceutically acceptable excipients for anti proliferative activity. 
       
         
           
           
               
               
           
         
       
     
     
         2 . A pharmaceutical composition comprising compound of formula 1 along with pharmaceutically acceptable excipients for the treatment of infections caused due to  M. tuberculosis.    
     
     
         3 . The pharmaceutical composition as claimed in  claim 1 , wherein the compound of formula 1 or formula 2 are present in the range of 0.1 to 99% w/w of total composition. 
     
     
         4 . The pharmaceutical composition as claimed in  claim 1 , wherein the pharmaceutically acceptable excipients are selected from the group comprising diluents, binders, lubricants, wetting agents, and disintegrants and their combinations thereof. 
     
     
         5 . A process for isolation of compound, said compound taken from the group of formula 1, formula 2 and/or formula 3, from the extract of aerial parts of  Anisomeles heyneana    said process comprising the steps of:   i. powdering aerial parts of  A. heyneana,  followed by extraction with acetone at temperature in the range of 25 to 30° C. followed by filtering and concentrating the acetone solubles under reduced pressure in the range of 50-100 mm Hg to obtain a greenish acetone extract;   ii. separating the extract as obtained in step (i) by using column chromatography (CC) with increasing polarity of the acetone in petroleum ether to afford 18 fractions (AH-1 to AH-18);   iii. subjecting Fraction AH7 as obtained in step (i) to CC in acetonitrile: chloroform gradient from 2 to 10% to collect six fractions (AH7a-AH7f);   iv. subjecting Fraction AH8 as obtained in step (i) to CC in acetonitrile: chloroform gradient from 2 to 10% to collect eight fractions (AH8a-AH8h);   v. combining Fractions AH8a, AH8b and AH7b as obtained in step (iii) and (iv) based on similarity of their TLC profile to obtain compound of formula 1 (80 mg) after CC in 1 to 5% methanol in chloroform;   vi. subjecting fraction AH-11 as obtained in step (i) to column chromatography in 1 to 5% of methanol in chloroform to obtain eleven sub fraction AH11a-AHk;   vii. subjecting Sub fraction AH11g as obtained in step (vi) to column chromatography in methanol in chloroform, to collect 8 sub fractions AH11g(i) to AH11g(viii) followed by purifying sub-fraction AH11g(ii) by washing with chloroform to obtain compound of formula 2;   viii. subjecting fraction AH-14 as obtained in step (i) to column chromatography in chloroform with acetonitrile from 5 to 50% to obtain fifteen fractions AH14a-AH14o;   ix. subjecting sub-fraction AH14k to preparative thin layer chromatography in 20-30% methanol in chloroform to afford brown amorphous powder of compound of formula 3.   
     
     
         6 . A method of treating a subject in need of anti proliferative agent comprising administrating a pharmaceutical composition as claimed in  claim 1 . 
     
     
         7 . A method of treating a subject suffering from  Mycobacterium tuberculosis  infections comprising administrating a pharmaceutical composition as claimed in  claim 2 . 
     
     
         8 . A method comprising use of a pharmaceutical composition of  claim 1  for anti proliferative activity 
       
         
           
           
               
               
           
         
       
     
     
         9 . A method comprising use of compound of formula 1 and 2 as claimed in  claim 8 , wherein said compounds exhibit 59 to 97% inhibition on Thp-1 cell line at 100 μg/ml. 
       
         
           
           
               
               
           
         
       
     
     
         10 . A method comprising use of a pharmaceutical composition of  claim 2  for the treatment of infections caused due to  M tuberculosis.    
       
         
           
           
               
               
           
         
       
     
     
         11 . A method comprising use of compound of formula 1 as claimed in  claim 10 , wherein said compound exhibit an IC 90  of 6.53±0.893 μg/ml. 
     
     
         12 . A method for the conversion of solar energy into electric current in dye sensitized solar cells, said method comprising use of compound of formula 3. 
       
         
           
           
               
               
           
         
       
     
     
         13 . The method of  claim 12 , wherein said compound exhibits 0.28% efficiency for the conversion of solar energy into electric current in dye sensitized solar cells. 
     
     
         14 . The pharmaceutical composition as claimed in  claim 2 , wherein the compound of formula 1 or formula 2 are present in the range of 0.1 to 99% w/w of total composition. 
     
     
         15 . The pharmaceutical composition as claimed in  claim 2 , wherein the pharmaceutically acceptable excipients are selected from the group comprising diluents, binders, lubricants, wetting agents, and disintegrants and their combinations thereof.